RICHMOND, Va., Dec 12, 2005 (BUSINESS WIRE) -- Insmed Incorporated (INSM) announced today the United States Food and Drug Administration (FDA) approved IPLEX(TM) (mecasermin rinfabate (rDNA origin) injection) for the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. As an orphan drug, IPLEX is entitled to seven years of marketing exclusivity for the treatment of Primary IGFD.
IP: Logged |
posted
Cruz already has a thread on this, I'll bring it up for ya.
Then just ask a Mod to remove the one you posted. I see your new, no problem, just check search for recent threads before ya post..Many times there is very good DD in them.
IP: Logged |
Topic Closed
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
